These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25826452)

  • 21. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
    Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
    Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
    Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
    Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
    Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
    Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.
    Viganò M; Serra G; Casella G; Grossi G; Lampertico P
    Expert Opin Biol Ther; 2016 Jul; 16(7):917-26. PubMed ID: 27088278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving testing for hepatitis B before treatment with rituximab.
    Dyson JK; Jopson L; Ng S; Lowery M; Harwood J; Waugh S; Valappil M; McPherson S
    Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1172-8. PubMed ID: 27388147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy.
    Kusumoto S; Tobinai K
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):576-83. PubMed ID: 25696914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence.
    Inuzuka T; Ueda Y; Morimura H; Fujii Y; Umeda M; Kou T; Osaki Y; Uemoto S; Chiba T; Marusawa H
    J Hepatol; 2014 Sep; 61(3):492-501. PubMed ID: 24798622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
    Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
    Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
    Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience.
    Junus K; Aguilar M; Patel P; Irwin D; Yee S; Liu B; Bhuket T; Wong RJ
    Cancer; 2017 Feb; 123(4):650-656. PubMed ID: 27696389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy.
    Montineri A; Nigro L; La Rosa R; Iacobello C; Larocca L; Cappello E; Fiumara PF; Di Raimondo F; Fatuzzo F
    J Clin Virol; 2011 Dec; 52(4):284-7. PubMed ID: 21906994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Tien YC; Yen HH; Chiu YM
    Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
    Tamori A; Hino M; Kawamura E; Fujii H; Uchida-Kobayashi S; Morikawa H; Nakamae H; Enomoto M; Murakami Y; Kawada N
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1715-21. PubMed ID: 24730465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
    Tanaka Y
    Rinsho Byori; 2016 Feb; 64(2):211-8. PubMed ID: 27311286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.